glenmark pharmaceuticals (GoldmanSachs) novel biologics outlicensed; enhances pipeline profile, Neutral

Date Rating Target Price Recommendation Price Broker house
17 May 2011 neutral 312 (from 320) 305 GoldmanSachs Report

No comments:

Post a Comment